Literature DB >> 8443028

CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers.

A L van Steveninck1, M S Pieters, H C Schoemaker, D D Breimer, A F Cohen.   

Abstract

1. The effects of metoprolol-Oros 14/190 once daily, propranolol 80 mg twice daily and temazepam 10 mg once daily on central nervous system (CNS) related performance and haemodynamic variables were evaluated in a double-blind, randomized, placebo controlled, crossover study in 12 healthy volunteers. Drugs were administered for 3 consecutive days except for temazepam, which was administered on days 1 and 3 only. Treatment effects were evaluated at 0, 2, 5 and 8 h on days 1 and 3. 2. Neither beta-adrenoceptor blocker had significant effects in a battery of tests after single or 3 days dosing. Temazepam caused a decrease in saccadic peak velocity of 37.4 degrees s-1 (95% CI: 6.0, 68.9) at 2 h and an increase of auditory reaction times of 11.5 ms (0.2, 22.8) at 8 h on day 1. No significant effects of temazepam were detected on day 3. 3. Both beta-adrenoceptor blockers reduced exercise heart rate. Peak effects were measured at 2 h 40 min after propranolol but not metoprolol-Oros (difference, day 1:20 (11, 29) beats min-1, day 3:13 (8, 19) beats min-1). Both beta-adrenoceptor blockers significantly reduced baseline exercise heart rate on day 3. Compared with day 1, metoprolol-Oros caused larger reductions of exercise heart rate at all times on day 3. 4. Metoprolol-Oros and propranolol caused similar reductions of systolic- and diastolic blood pressure on days 1 and 3. Temazepam caused a small reduction in diastolic blood pressure at 5 h 40 min on day 1 but was otherwise devoid of haemodynamic effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443028      PMCID: PMC1381501          DOI: 10.1111/j.1365-2125.1993.tb05676.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

Review 1.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

2.  Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties.

Authors:  J B Kostis; R C Rosen
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

3.  Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.

Authors:  A Racine-Poon; J Moppert
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

4.  Comparison of single-dose pharmacokinetic and pharmacodynamic properties of two metoprolol Oros systems with different initial zero-order release rates.

Authors:  S J Warrington; S P Barclay; V A John; P A Shotton; W Good
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

5.  Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

Authors:  F Theeuwes; D R Swanson; G Guittard; A Ayer; S Khanna
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

6.  A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.

Authors:  K L Woods; D B Jack; M J Kendall; A Halsey; M L O'Donnell; S J Warrington; V A John
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension.

Authors:  M J Serlin; M L Orme; M MacIver; G J Green; R G Sibeon; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

8.  A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers.

Authors:  A L van Steveninck; H C Schoemaker; M S Pieters; R Kroon; D D Breimer; A F Cohen
Journal:  Clin Pharmacol Ther       Date:  1991-08       Impact factor: 6.875

9.  Controlled-release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline.

Authors:  C G Löfdahl; C Dahlöf; G Westergren; B Olofsson; N Svedmyr
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 10.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

View more
  2 in total

Review 1.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

2.  Decreasing the Burden of Side Effects Through Positive Message Framing: an Experimental Proof-of-Concept Study.

Authors:  Marcel Wilhelm; Winfried Rief; Bettina K Doering
Journal:  Int J Behav Med       Date:  2018-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.